Case Report: The Utilization of Crizotinib and Brentuximab Vedotin as a Bridge to Autologous Stem Cell Transplantation and Followed by CD30-directed CAR-T Cell Therapy in Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Wanying Liu1
Jiaying Wu1
Xi Ming1
Qi Zhang1
Delian Zhou1
Rubng Zheng1
Liting Chen1*
Xiaojian Zhu1*
Yi Xiao1*
- 1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Background: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare, mature T-cell non-Hodgkin lymphoma. The prognosis of patients with relapsed or refractory ALCL following first-line chemotherapy is extremely poor. NCCN guidelines recommend intensified chemotherapy with or without ASCT consolidation for r/r ALCL, however, this is not an effective treatment for all ALK+ALCL. Case report: Herein, we report a patient with relapsed/refractory ALK+ ALCL who received crizotinib and brentuximab vedotin as bridging therapy, followed by autologous stem cell transplantation and sequential anti-CD30 CAR T cell therapy. Conclusion: The patient achieved complete remission and long-term disease-free survival of months and continues to be followed up. The combination therapy model in this case may provide guidance for the management of relapsed/refractory ALK+ ALCL, and further prospective trials are needed to confirm its effectiveness.
Keywords: Anaplastic large cell lymphoma, T-cell non-Hodgkin lymphoma, crizotinib, CAR T cell therapy, Autologous stem cell transplantation
Received: 28 Nov 2023;
Accepted: 16 Jan 2024.
Copyright: © 2024 Liu, Wu, Ming, Zhang, Zhou, Zheng, Chen, Zhu and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dr. Liting Chen, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China
Dr. Xiaojian Zhu, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China
Dr. Yi Xiao, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China